BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19020717)

  • 1. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
    Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
    Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
    Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
    Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
    Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
    Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
    Inami K; Abe M; Takeda K; Hagiwara Y; Maeda M; Segawa T; Suyama M; Watanabe S; Hino O
    Cancer Sci; 2010 Apr; 101(4):969-74. PubMed ID: 20100205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
    Hagiwara Y; Hamada Y; Kuwahara M; Maeda M; Segawa T; Ishikawa K; Hino O
    Cancer Sci; 2008 Apr; 99(4):666-70. PubMed ID: 18294289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
    Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
    Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin: a new target for immunotherapy.
    Hassan R; Bera T; Pastan I
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3937-42. PubMed ID: 15217923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
    Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
    Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.
    Nakaishi M; Kajino K; Ikesue M; Hagiwara Y; Kuwahara M; Mitani H; Horikoshi-Sakuraba Y; Segawa T; Kon S; Maeda M; Wang T; Abe M; Yokoyama M; Hino O
    Cancer Sci; 2007 May; 98(5):659-64. PubMed ID: 17425688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
    Maeda M; Hino O
    Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.
    Ito T; Kajino K; Abe M; Sato K; Maekawa H; Sakurada M; Orita H; Wada R; Kajiyama Y; Hino O
    Oncol Rep; 2014 Jan; 31(1):27-33. PubMed ID: 24146039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
    Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
    Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
    Argani P; Iacobuzio-Donahue C; Ryu B; Rosty C; Goggins M; Wilentz RE; Murugesan SR; Leach SD; Jaffee E; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Clin Cancer Res; 2001 Dec; 7(12):3862-8. PubMed ID: 11751476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.
    Rosty C; Christa L; Kuzdzal S; Baldwin WM; Zahurak ML; Carnot F; Chan DW; Canto M; Lillemoe KD; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Cancer Res; 2002 Mar; 62(6):1868-75. PubMed ID: 11912167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
    Iacobuzio-Donahue CA; Ashfaq R; Maitra A; Adsay NV; Shen-Ong GL; Berg K; Hollingsworth MA; Cameron JL; Yeo CJ; Kern SE; Goggins M; Hruban RH
    Cancer Res; 2003 Dec; 63(24):8614-22. PubMed ID: 14695172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.
    Ryu B; Jones J; Blades NJ; Parmigiani G; Hollingsworth MA; Hruban RH; Kern SE
    Cancer Res; 2002 Feb; 62(3):819-26. PubMed ID: 11830538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
    Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
    Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.